This report aims to provide a comprehensive presentation of the global market for Hospital-acquired Pneumonia (HAP) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-acquired Pneumonia (HAP) Drugs. This report contains market size and forecasts of Hospital-acquired Pneumonia (HAP) Drugs in global, including the following market information:
Global Hospital-acquired Pneumonia (HAP) Drugs Market Revenue, 2019-2024, 2024-2029, ($ millions)
Global Hospital-acquired Pneumonia (HAP) Drugs Market Sales, 2019-2024, 2024-2029, (K Pcs)
Global top five Hospital-acquired Pneumonia (HAP) Drugs companies in 2023 (%)
The global Hospital-acquired Pneumonia (HAP) Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Antibacterial Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hospital-acquired Pneumonia (HAP) Drugs include Pfizer, GlaxoSmithKline, Merck, Mylan, Novartis, Teva Pharmaceutical Industries, AstraZeneca, Arsanis and Combioxin, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hospital-acquired Pneumonia (HAP) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hospital-acquired Pneumonia (HAP) Drugs Market, by Type, 2019-2024, 2024-2029 ($ Millions) & (K Pcs)
Global Hospital-acquired Pneumonia (HAP) Drugs Market Segment Percentages, by Type, 2023 (%)
Antibacterial
Antiviral
Antifungal
Global Hospital-acquired Pneumonia (HAP) Drugs Market, by Application, 2019-2024, 2024-2029 ($ Millions) & (K Pcs)
Global Hospital-acquired Pneumonia (HAP) Drugs Market Segment Percentages, by Application, 2023 (%)
Hospitals
Clinics
Other
Global Hospital-acquired Pneumonia (HAP) Drugs Market, By Region and Country, 2019-2024, 2024-2029 ($ Millions) & (K Pcs)
Global Hospital-acquired Pneumonia (HAP) Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hospital-acquired Pneumonia (HAP) Drugs revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Hospital-acquired Pneumonia (HAP) Drugs revenues share in global market, 2023 (%)
Key companies Hospital-acquired Pneumonia (HAP) Drugs sales in global market, 2019-2024 (Estimated), (K Pcs)
Key companies Hospital-acquired Pneumonia (HAP) Drugs sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
GlaxoSmithKline
Merck
Mylan
Novartis
Teva Pharmaceutical Industries
AstraZeneca
Arsanis
Combioxin
Shinogi
Sun Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hospital-acquired Pneumonia (HAP) Drugs, market overview.
Chapter 2: Global Hospital-acquired Pneumonia (HAP) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Hospital-acquired Pneumonia (HAP) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hospital-acquired Pneumonia (HAP) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hospital-acquired Pneumonia (HAP) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hospital-acquired Pneumonia (HAP) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hospital-acquired Pneumonia (HAP) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hospital-acquired Pneumonia (HAP) Drugs Overall Market Size
2.1 Global Hospital-acquired Pneumonia (HAP) Drugs Market Size: 2022 VS 2031
2.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, Prospects & Forecasts: 2019-2031
2.3 Global Hospital-acquired Pneumonia (HAP) Drugs Sales: 2019-2031
3 Company Landscape
3.1 Top Hospital-acquired Pneumonia (HAP) Drugs Players in Global Market
3.2 Top Global Hospital-acquired Pneumonia (HAP) Drugs Companies Ranked by Revenue
3.3 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue by Companies
3.4 Global Hospital-acquired Pneumonia (HAP) Drugs Sales by Companies
3.5 Global Hospital-acquired Pneumonia (HAP) Drugs Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Hospital-acquired Pneumonia (HAP) Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Hospital-acquired Pneumonia (HAP) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Hospital-acquired Pneumonia (HAP) Drugs Players in Global Market
3.8.1 List of Global Tier 1 Hospital-acquired Pneumonia (HAP) Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Hospital-acquired Pneumonia (HAP) Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Market Size Markets, 2022 & 2031
4.1.2 Antibacterial
4.1.3 Antiviral
4.1.4 Antifungal
4.2 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue & Forecasts
4.2.1 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2024
4.2.2 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2024-2031
4.2.3 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
4.3 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Sales & Forecasts
4.3.1 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Sales, 2019-2024
4.3.2 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Sales, 2024-2031
4.3.3 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
4.4 By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Price (Manufacturers Selling Prices), 2019-2031
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2022 & 2031
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Other
5.2 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue & Forecasts
5.2.1 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2024
5.2.2 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2024-2031
5.2.3 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
5.3 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Sales & Forecasts
5.3.1 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Sales, 2019-2024
5.3.2 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Sales, 2024-2031
5.3.3 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
5.4 By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Price (Manufacturers Selling Prices), 2019-2031
6 Sights by Region
6.1 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2022 & 2031
6.2 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue & Forecasts
6.2.1 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2024
6.2.2 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2024-2031
6.2.3 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
6.3 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Sales & Forecasts
6.3.1 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Sales, 2019-2024
6.3.2 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Sales, 2024-2031
6.3.3 By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
6.4 North America
6.4.1 By Country - North America Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2031
6.4.2 By Country - North America Hospital-acquired Pneumonia (HAP) Drugs Sales, 2019-2031
6.4.3 US Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.4.4 Canada Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.4.5 Mexico Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.5 Europe
6.5.1 By Country - Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2031
6.5.2 By Country - Europe Hospital-acquired Pneumonia (HAP) Drugs Sales, 2019-2031
6.5.3 Germany Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.5.4 France Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.5.5 U.K. Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.5.6 Italy Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.5.7 Russia Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.5.8 Nordic Countries Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.5.9 Benelux Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.6 Asia
6.6.1 By Region - Asia Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2031
6.6.2 By Region - Asia Hospital-acquired Pneumonia (HAP) Drugs Sales, 2019-2031
6.6.3 China Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.6.4 Japan Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.6.5 South Korea Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.6.6 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.6.7 India Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.7 South America
6.7.1 By Country - South America Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2031
6.7.2 By Country - South America Hospital-acquired Pneumonia (HAP) Drugs Sales, 2019-2031
6.7.3 Brazil Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.7.4 Argentina Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2031
6.8.2 By Country - Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales, 2019-2031
6.8.3 Turkey Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.8.4 Israel Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.8.5 Saudi Arabia Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
6.8.6 UAE Hospital-acquired Pneumonia (HAP) Drugs Market Size, 2019-2031
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.1.4 Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.1.5 Pfizer Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.2.4 GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Merck
7.3.1 Merck Company Summary
7.3.2 Merck Business Overview
7.3.3 Merck Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.3.4 Merck Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.3.5 Merck Key News & Latest Developments
7.4 Mylan
7.4.1 Mylan Company Summary
7.4.2 Mylan Business Overview
7.4.3 Mylan Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.4.4 Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.4.5 Mylan Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.5.4 Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.5.5 Novartis Key News & Latest Developments
7.6 Teva Pharmaceutical Industries
7.6.1 Teva Pharmaceutical Industries Company Summary
7.6.2 Teva Pharmaceutical Industries Business Overview
7.6.3 Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.6.4 Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.6.5 Teva Pharmaceutical Industries Key News & Latest Developments
7.7 AstraZeneca
7.7.1 AstraZeneca Company Summary
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.7.4 AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.7.5 AstraZeneca Key News & Latest Developments
7.8 Arsanis
7.8.1 Arsanis Company Summary
7.8.2 Arsanis Business Overview
7.8.3 Arsanis Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.8.4 Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.8.5 Arsanis Key News & Latest Developments
7.9 Combioxin
7.9.1 Combioxin Company Summary
7.9.2 Combioxin Business Overview
7.9.3 Combioxin Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.9.4 Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.9.5 Combioxin Key News & Latest Developments
7.10 Shinogi
7.10.1 Shinogi Company Summary
7.10.2 Shinogi Business Overview
7.10.3 Shinogi Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.10.4 Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.10.5 Shinogi Key News & Latest Developments
7.11 Sun Pharmaceutical Industries
7.11.1 Sun Pharmaceutical Industries Company Summary
7.11.2 Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Business Overview
7.11.3 Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.11.4 Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.11.5 Sun Pharmaceutical Industries Key News & Latest Developments
7.12 The Medicines Company
7.12.1 The Medicines Company Company Summary
7.12.2 The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Business Overview
7.12.3 The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.12.4 The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.12.5 The Medicines Company Key News & Latest Developments
7.13 Theravance Biopharma
7.13.1 Theravance Biopharma Company Summary
7.13.2 Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Business Overview
7.13.3 Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Major Product Offerings
7.13.4 Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Sales and Revenue in Global (2019-2024)
7.13.5 Theravance Biopharma Key News & Latest Developments
8 Global Hospital-acquired Pneumonia (HAP) Drugs Production Capacity, Analysis
8.1 Global Hospital-acquired Pneumonia (HAP) Drugs Production Capacity, 2019-2031
8.2 Hospital-acquired Pneumonia (HAP) Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Hospital-acquired Pneumonia (HAP) Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Hospital-acquired Pneumonia (HAP) Drugs Supply Chain Analysis
10.1 Hospital-acquired Pneumonia (HAP) Drugs Industry Value Chain
10.2 Hospital-acquired Pneumonia (HAP) Drugs Upstream Market
10.3 Hospital-acquired Pneumonia (HAP) Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Hospital-acquired Pneumonia (HAP) Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Hospital-acquired Pneumonia (HAP) Drugs in Global Market
Table 2. Top Hospital-acquired Pneumonia (HAP) Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue by Companies, (US$, Mn), 2019-2024
Table 4. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Companies, 2019-2024
Table 5. Global Hospital-acquired Pneumonia (HAP) Drugs Sales by Companies, (K Pcs), 2019-2024
Table 6. Global Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Companies, 2019-2024
Table 7. Key Manufacturers Hospital-acquired Pneumonia (HAP) Drugs Price (2019-2024) & (USD/Pcs)
Table 8. Global Manufacturers Hospital-acquired Pneumonia (HAP) Drugs Product Type
Table 9. List of Global Tier 1 Hospital-acquired Pneumonia (HAP) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hospital-acquired Pneumonia (HAP) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2022 & 2031
Table 12. By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue (US$, Mn), 2019-2024
Table 13. By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue (US$, Mn), 2024-2031
Table 14. By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), 2019-2024
Table 15. By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), 2024-2031
Table 16. By Application ? Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2022 & 2031
Table 17. By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue (US$, Mn), 2019-2024
Table 18. By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue (US$, Mn), 2024-2031
Table 19. By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), 2019-2024
Table 20. By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), 2024-2031
Table 21. By Region ? Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2022 VS 2031
Table 22. By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue (US$, Mn), 2019-2024
Table 23. By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue (US$, Mn), 2024-2031
Table 24. By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), 2019-2024
Table 25. By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), 2024-2031
Table 26. By Country - North America Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2024
Table 27. By Country - North America Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2024-2031
Table 28. By Country - North America Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2019-2024
Table 29. By Country - North America Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2024-2031
Table 30. By Country - Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2024
Table 31. By Country - Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2024-2031
Table 32. By Country - Europe Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2019-2024
Table 33. By Country - Europe Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2024-2031
Table 34. By Region - Asia Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2024
Table 35. By Region - Asia Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2024-2031
Table 36. By Region - Asia Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2019-2024
Table 37. By Region - Asia Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2024-2031
Table 38. By Country - South America Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2024
Table 39. By Country - South America Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2024-2031
Table 40. By Country - South America Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2019-2024
Table 41. By Country - South America Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2024-2031
Table 42. By Country - Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2024
Table 43. By Country - Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2024-2031
Table 44. By Country - Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2019-2024
Table 45. By Country - Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales, (K Pcs), 2024-2031
Table 46. Pfizer Company Summary
Table 47. Pfizer Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 48. Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 49. Pfizer Key News & Latest Developments
Table 50. GlaxoSmithKline Company Summary
Table 51. GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 52. GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 53. GlaxoSmithKline Key News & Latest Developments
Table 54. Merck Company Summary
Table 55. Merck Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 56. Merck Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 57. Merck Key News & Latest Developments
Table 58. Mylan Company Summary
Table 59. Mylan Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 60. Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 61. Mylan Key News & Latest Developments
Table 62. Novartis Company Summary
Table 63. Novartis Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 64. Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 65. Novartis Key News & Latest Developments
Table 66. Teva Pharmaceutical Industries Company Summary
Table 67. Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 68. Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 69. Teva Pharmaceutical Industries Key News & Latest Developments
Table 70. AstraZeneca Company Summary
Table 71. AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 72. AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 73. AstraZeneca Key News & Latest Developments
Table 74. Arsanis Company Summary
Table 75. Arsanis Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 76. Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 77. Arsanis Key News & Latest Developments
Table 78. Combioxin Company Summary
Table 79. Combioxin Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 80. Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 81. Combioxin Key News & Latest Developments
Table 82. Shinogi Company Summary
Table 83. Shinogi Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 84. Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 85. Shinogi Key News & Latest Developments
Table 86. Sun Pharmaceutical Industries Company Summary
Table 87. Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 88. Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 89. Sun Pharmaceutical Industries Key News & Latest Developments
Table 90. The Medicines Company Company Summary
Table 91. The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 92. The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 93. The Medicines Company Key News & Latest Developments
Table 94. Theravance Biopharma Company Summary
Table 95. Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Product Offerings
Table 96. Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 97. Theravance Biopharma Key News & Latest Developments
Table 98. Hospital-acquired Pneumonia (HAP) Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2024 (K Pcs)
Table 99. Global Hospital-acquired Pneumonia (HAP) Drugs Capacity Market Share of Key Manufacturers, 2021-2024
Table 100. Global Hospital-acquired Pneumonia (HAP) Drugs Production by Region, 2019-2024 (K Pcs)
Table 101. Global Hospital-acquired Pneumonia (HAP) Drugs Production by Region, 2024-2031 (K Pcs)
Table 102. Hospital-acquired Pneumonia (HAP) Drugs Market Opportunities & Trends in Global Market
Table 103. Hospital-acquired Pneumonia (HAP) Drugs Market Drivers in Global Market
Table 104. Hospital-acquired Pneumonia (HAP) Drugs Market Restraints in Global Market
Table 105. Hospital-acquired Pneumonia (HAP) Drugs Raw Materials
Table 106. Hospital-acquired Pneumonia (HAP) Drugs Raw Materials Suppliers in Global Market
Table 107. Typical Hospital-acquired Pneumonia (HAP) Drugs Downstream
Table 108. Hospital-acquired Pneumonia (HAP) Drugs Downstream Clients in Global Market
Table 109. Hospital-acquired Pneumonia (HAP) Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Hospital-acquired Pneumonia (HAP) Drugs Segment by Type in 2022
Figure 2. Hospital-acquired Pneumonia (HAP) Drugs Segment by Application in 2022
Figure 3. Global Hospital-acquired Pneumonia (HAP) Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Hospital-acquired Pneumonia (HAP) Drugs Market Size: 2022 VS 2031 (US$, Mn)
Figure 6. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, 2019-2031 (US$, Mn)
Figure 7. Hospital-acquired Pneumonia (HAP) Drugs Sales in Global Market: 2019-2031 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Hospital-acquired Pneumonia (HAP) Drugs Revenue in 2022
Figure 9. By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2022 & 2031
Figure 10. By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
Figure 11. By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
Figure 12. By Type - Global Hospital-acquired Pneumonia (HAP) Drugs Price (USD/Pcs), 2019-2031
Figure 13. By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2022 & 2031
Figure 14. By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
Figure 15. By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
Figure 16. By Application - Global Hospital-acquired Pneumonia (HAP) Drugs Price (USD/Pcs), 2019-2031
Figure 17. By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2022 & 2031
Figure 18. By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019 VS 2022 VS 2031
Figure 19. By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
Figure 20. By Region - Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
Figure 21. By Country - North America Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
Figure 22. By Country - North America Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
Figure 23. US Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 24. Canada Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 25. Mexico Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 26. By Country - Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
Figure 27. By Country - Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
Figure 28. Germany Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 29. France Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 30. U.K. Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 31. Italy Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 32. Russia Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 33. Nordic Countries Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 34. Benelux Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 35. By Region - Asia Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
Figure 36. By Region - Asia Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
Figure 37. China Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 38. Japan Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 39. South Korea Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 40. Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 41. India Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 42. By Country - South America Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
Figure 43. By Country - South America Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
Figure 44. Brazil Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 45. Argentina Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 46. By Country - Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share, 2019-2031
Figure 47. By Country - Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share, 2019-2031
Figure 48. Turkey Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 49. Israel Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 50. Saudi Arabia Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 51. UAE Hospital-acquired Pneumonia (HAP) Drugs Revenue, (US$, Mn), 2019-2031
Figure 52. Global Hospital-acquired Pneumonia (HAP) Drugs Production Capacity (K Pcs), 2019-2031
Figure 53. The Percentage of Production Hospital-acquired Pneumonia (HAP) Drugs by Region, 2022 VS 2031
Figure 54. Hospital-acquired Pneumonia (HAP) Drugs Industry Value Chain
Figure 55. Marketing Channels
